Hyundai has utilised its patented drug delivery system technology to repurpose Niclosamide effectively. Credit: BlurryMe/Shutterstock.com.

Hyundai Bioscience has announced plans to conduct clinical trials in Brazil for its Niclosamide-based Dengue antiviral.

The company’s decision comes after it carried several consultations with clinical research organisations worldwide.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Brazil, known for having the highest number of Dengue cases globally, offers a conducive environment for such trials with its fast-track approval process, the company said.

Hyundai has utilised its patented drug delivery system technology, which employs inorganics and polymers harmless to humans, to repurpose Niclosamide effectively.

This innovation has addressed the low bioavailability and short half-life issues of the therapy, demonstrating pan-serotype antiviral efficacy against Dengue in past in vitro studies.

See Also:

Hyundai Bioscience has developed a formulation that achieves the required drug concentration to inhibit the proliferation of not only the four Dengue virus serotypes but also Chikungunya, Zika and Yellow fever viruses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company emphasises the importance of early treatment, which is viable with this broad-spectrum antiviral, especially before the viral load surges.

In the planned basket-type clinical trial in Brazil, the antiviral will be administered to patients infected with any of the four Dengue virus serotypes or other mosquito-borne viruses.

The trial aims to evaluate the drug’s efficacy specifically in the Dengue-confirmed patient population.

Hyundai Bioscience USA CEO Dr Kim Kyung-Il said: “The success of Dengue clinical study on our Niclosamide-based antiviral could lead to its emergency use authorisation not only in Brazil but also in other countries. We plan to set the supply price in the $100 range.”

In 2022, Hyundai Bioscience announced the Phase II clinical trial of a new broad-spectrum antiviral agent, CP-COV03, for the treatment of Covid-19 patients.